What qualifies as “robust” when it comes to data? Is digital health a bubble? And can Gilead Sciences (GILD) survive without men named John?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about those new Alzheimer’s disease results from Biogen (BIIB) and Eisai that, while ostensibly positive, have left many people scratching their heads. Then we’re joined by health care venture capitalist Lisa Suennen, who explains why there’s so much money flowing into digital health — and why some of it might as well be set on fire. And finally we’ll mark the end of an era at Gilead and speculate baselessly about who’s going to lead the company in the future.